C. JANE BREEDEN, A.B.; THOMAS C. HALL, M.D., F.A.C.P.; H. RICHARD TYLER, M.D.
Acute necrotizing encephalitis due to herpes simplex virus can be a fatal or severely debilitating disease (1-4). The outlook is especially poor in those patients in whom the disease progresses to coma and convulsions (1, 2).
An analogue of thymidine, 5-iodo-2′deoxyuridine (IUDR), inhibits the growth of herpes simplex and other deoxyribonucleic acid (DNA) viruses in vitro (5, 6) and has been used topically in the treatment of herpes simplex keratitis (7, 8).
It has been suggested that systemic IUDR might be helpful in slowing or aborting the progression of potentially lethal systemic viral diseases such as herpes simplex encephalitis (7,
BREEDEN CJ, HALL TC, TYLER HR. Herpes Simplex Encephalitis Treated with Systemic 5-Iodo-2′deoxyuridine. Ann Intern Med. ;65:1050–1056. doi: 10.7326/0003-4819-65-5-1050
Download citation file:
Published: Ann Intern Med. 1966;65(5):1050-1056.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use